Prolongation of the QT interval on an electrocardiogram (ECG) represents a significant electrical abnormality of the ventricular repolarization phase. This metric is crucial because it reflects the heart’s recovery period, and its extension creates a vulnerable window that can precipitate dangerous arrhythmias. While the interval is influenced by inherent patient factors like genetics and autonomic tone, a substantial portion of clinically relevant prolongation is driven by external triggers. Understanding the multifaceted causes of QTc prolongation is essential for clinicians aiming to prevent iatrogenic complications and for researchers developing safer pharmacological therapies.
Primary Pharmacological Drivers
The most common and clinically significant cause of acquired QTc prolongation is medication. A wide array of drug classes can interfere with the cardiac potassium channels, specifically the IKs current, which is responsible for repolarization. This pharmacological blockade delays the return of the ventricular myocytes to their resting state, effectively stretching the electrical cycle. The risk is not limited to experimental compounds; frequently prescribed antibiotics, antiemetics, and psychiatric medications are frequent offenders in clinical practice.
Cardiovascular and Antibiotic Agents
Within the cardiovascular realm, specific antiarrhythmic drugs are well-known for their pro-arrhythmic potential, particularly Class III agents which inherently target repolarization. However, other classes contribute significantly to risk. Macrolide antibiotics, such as azithromycin and clarithromycin, and fluoroquinolones like levofloxacin, are frequently implicated in clinical settings. These drugs often block the hERG potassium channel, and their effect is amplified in the presence of comorbidities or concurrent metabolic disturbances.
Psychiatric and Antiemetic Medications
Psychiatric medications represent another major category. Antipsychotics, including both typical agents like haloperidol and atypical agents like risperidone, carry a black box warning for QTc effects. Similarly, certain antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), can subtly or severely prolong the interval. Antiemetics, especially ondansetron and droperidol, are potent disruptors of ventricular repolarization and are often encountered in acute care settings.
Metabolic and Electrolyte Derangements
Electrolyte abnormalities are potent physiological amplifiers of QTc prolongation. The cardiac action potential relies on a precise gradient of sodium, potassium, calcium, and magnesium. Disruption of this balance directly impacts the ionic currents governing repolarization. Unlike pharmacological blockade, which is often dose-dependent, metabolic disturbances can turn a previously safe QT interval into a dangerous one with rapid shifts.
Hypokalemia and Hypomagnesemia
Hypokalemia, or low serum potassium, is a classic and critical culprit. Low extracellular potassium slows the repolarizing potassium currents, necessitating a longer time to reset the cellular voltage. Similarly, hypomagnesemia is an independent risk factor; magnesium acts as a natural calcium channel blocker, and its deficiency removes a stabilizing influence on the cardiac cell membrane. The combination of low potassium and low magnesium is particularly dangerous and synergistic in its effect on prolonging the QTc interval.
Hypocalcemia and Other Factors
Hypocalcemia, while classically associated with the corrected QT (QTc), has a more complex relationship. It primarily affects the ST segment, often making the interval appear longer on the ECG, even if the underlying repolarization reserve is intact. Furthermore, conditions leading to bradycardia, such as high-degree atrioventricular (AV) block, inherently prolong the QTc simply because the heart rate is a major correcting factor in the calculation formula.
